Neuropathy News and Research

RSS

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, in combination with bortezomib and dexamethasone, showed an 83 percent overall response rate (n=5/6) in bortezomib-naive patients with relapsed/refractory (R/R) multiple myeloma, including two patients who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, in Chicago.

1 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.

30 May 2015

Charcot foot increasing among diabetics

A growing number of diabetics are being diagnosed with a debilitating foot deformity called Charcot foot. Charcot foot often confines patients to wheelchairs, and in severe cases can require amputation.

28 May 2015

Scientists find new way to convert blood cells into sensory neurons

Scientists at McMaster University have discovered how to make adult sensory neurons from human patients simply by having them roll up their sleeve and providing a blood sample.

22 May 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

Mifepristone-eribulin combination clinically active in triple-negative breast cancer patients

Corcept Therapeutics Incorporated, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin (Halaven) that show it is well tolerated and clinically active in patients with triple-negative breast cancer.

15 May 2015

Pain management webinar addresses fibromyalgia, "the invisible disease"

Topical BioMedics is hosting its free monthly pain management webinar on Tuesday, May 12th, focusing on the topic “What You need to Know about Fibromyalgia.” The webinar, which is free and open to the public, will be streamed live from 12pm to 1pm, then archived and accessible on demand 24/7...

7 May 2015

Omega-3 fatty acids in fish oil can restore nerves damaged from diabetes

Approximately 50 percent of patients with diabetes suffer from nerve damage, or neuropathy. No cure exists, and the most effective treatment, keeping blood sugar in control, only slows neuropathy.

7 May 2015

Diabetic neuropathy highly prevalent among diabetic patients in Romania

A survey of 25,000 Romanians with diabetes has revealed that diabetic neuropathy (DN), a complication of diabetes, is highly prevalent in these patients, even in the absence of a diagnostic, and has an important impact on patients' quality of life.

6 May 2015

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).

24 Apr 2015

Discovery unveils novel drug targets to halt peripheral neuropathies, neurodegenerative disorders

New research highlights how nerves - whether harmed by disease or traumatic injury - start to die, a discovery that unveils novel targets for developing drugs to slow or halt peripheral neuropathies and devastating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS).

22 Apr 2015

Inflammation plays causal role in neurologic changes associated with Lyme disease

About 15% of patients with Lyme disease develop peripheral and central nervous system involvement, often accompanied by debilitating and painful symptoms. New research indicates that inflammation plays a causal role in the array of neurologic changes associated with Lyme disease, according to a study published in The American Journal of Pathology.

17 Apr 2015

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.

6 Apr 2015

Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo. In addition, a strong safety profile for the product was observed.

30 Mar 2015

Patients with carpal tunnel syndrome twice as likely to have migraine headaches, shows study

Patients with carpal tunnel syndrome are more than twice as likely to have migraine headaches, reports a study in Plastic and Reconstructive Surgery--Global Open, the official open-access medical journal of the American Society of Plastic Surgeons (ASPS).

24 Mar 2015

Targeted drug doubles progression free survival in Hodgkin lymphoma

A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo (43 months vs 24 months).

19 Mar 2015

Neuropathy News and Research

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Charcot foot increasing among diabetics

Scientists find new way to convert blood cells into sensory neurons

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Mifepristone-eribulin combination clinically active in triple-negative breast cancer patients

Pain management webinar addresses fibromyalgia, "the invisible disease"

Omega-3 fatty acids in fish oil can restore nerves damaged from diabetes

Diabetic neuropathy highly prevalent among diabetic patients in Romania

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Discovery unveils novel drug targets to halt peripheral neuropathies, neurodegenerative disorders

Inflammation plays causal role in neurologic changes associated with Lyme disease

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

Patients with carpal tunnel syndrome twice as likely to have migraine headaches, shows study

Targeted drug doubles progression free survival in Hodgkin lymphoma

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Sildenafil drug may effectively relieve nerve damage in men with long-term diabetes

TCC-EZ Casting System dramatically increases healing process of diabetic foot ulcers

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News